Successful treatment with Tislelizumab and Zanubrutinib in a patient with relapsed/refractory, CD19/CD20 negative Richter’s transformed CLL
- 15 October 2025
- journal article
- other
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (1) , 98-100
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapyBlood, 2024
- Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialNature Medicine, 2023
- A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLBlood Advances, 2023
- Biology and Treatment of Richter TransformationFrontiers in Oncology, 2022
- Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell TherapyNew England Journal of Medicine, 2021
- Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsLeukemia, 2020
- Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment StrategiesFrontiers in Immunology, 2019
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaNature Medicine, 2018
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphomaHaematologica, 2018
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016